Pacira BioSciences Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Pacira Pharma (PCRX) Misses Q2 EPS by 35c
August 3, 2022 8:06 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.53, $0.35 worse than the analyst estimate of $0.88. Revenue for the quarter came in at $169.4 million versus the consensus estimate of $172.22 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More